(Q37989006)

26 August 2017

title

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? (English)

1 reference

26 August 2017

1 reference

lymphoblastic leukemia

1 reference

Dario Campana

1

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Current hematologic malignancy reports

26 August 2017

published in

1 reference

26 August 2017

volume

7

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

170-177

1 reference

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

New markers for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Comm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris)

21 January 2018

1 reference

12 December 2020

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

1 reference

12 December 2020

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

1 reference

12 December 2020

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

1 reference

12 December 2020

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences

1 reference

12 December 2020

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

1 reference

12 December 2020

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

1 reference

12 December 2020

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

12 December 2020

The immunologic detection of minimal residual disease in acute leukemia.

1 reference

12 December 2020

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

1 reference

12 December 2020

Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia

1 reference

12 December 2020

Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

12 December 2020

bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

In vitro amplification of T cell gamma gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias

1 reference

12 December 2020

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

12 December 2020

Minimal residual disease in acute lymphoblastic leukemia

1 reference

12 December 2020

10.1007/S11899-012-0115-4

Identifiers

DOI

1 reference

26 August 2017

1 reference